Compare Amphastar Pharmaceuticals Inc (AMPH) vs IAC/Interactivecorp (PPLI) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

PPLI trades at $46.50, down 2.13% on the day, near its 52-week high. The stock shows bullish technical signals with strong moving average support, though RSI levels suggest overbought conditions. Fundamentally, revenue has declined from $5.2B in 2022 to $2.4B in 2025, with recent quarters missing EPS expectations. The company maintains a high gross margin of 66.49% but struggles with profitability, posting a net loss of $104M in 2025. Analyst consensus remains bullish with a $55.40 price target, while recent news questions valuation after a 3.6% rally.

PPLI presents a mixed outlook with bullish analyst sentiment against challenging fundamentals. The 63.64% buy rating and 25% upside to consensus target reflect optimism for a turnaround, but consecutive earnings misses and negative cash flow pose significant execution risks. Investors face volatility from inconsistent profitability despite attractive valuation metrics like P/B of 0.76. The key catalyst remains demonstrating sustainable earnings growth amid declining revenues.